Aurobindo Pharma surges as its arm inks voluntary license with Medicines Patent Pool
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
Aurobindo Pharma is currently trading at Rs. 696.05, up by 24.85 points or 3.70% from its previous closing of Rs. 671.20 on the BSE.
The scrip opened at Rs. 671.00 and has touched a high and low of Rs. 700.85 and Rs. 665.65 respectively. So far 66365 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 700.85 on 23-Jun-2023 and a 52 week low of Rs. 397.30 on 03-Feb-2023.
Last one week high and low of the scrip stood at Rs. 700.85 and Rs. 665.65 respectively. The current market cap of the company is Rs. 40722.73 crore.
The promoters holding in the company stood at 51.83%, while Institutions and Non-Institutions held 38.11% and 10.05% respectively.
Aurobindo Pharma’s wholly owned subsidiary company -- Eugia Pharma Specialties has entered voluntary sub-licensing agreement with Medicines Patent Pool (MPP), to develop and market Nilotinib Capsules, originally developed by Novartis, for the treatment of chronic myeloid leukemia (CML) in 44 Low and Middle-Income Countries (LMIC), including the seven countries where patents on the product are pending or in force.
The product will be produced at the Eugia Pharma Specialities Unit-I, Medchal, Malkajgiri District, Telangana, India. The company has adequate capacities of world class standards, to meet the global demand for the product across the licensed territory.
Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.
